Pharmacy Times March 25, 2023
Alana Hippensteele, Managing Editor

Specifically, non-opioids are often preferred for the management of subacute and chronic pain because of their safety profiles.

In 2019, a National Health Interview Survey (NHIS) showed that a significant number of patients were living with chronic pain, which is considered to be pain lasting longer than 3 months, or high impact pain, which is pain that is affecting a patient’s daily activities on most days of the week within the past 3 months, according to Emily E. Leppien, PharmD, BCPS, BCPP, during a presentation at the APhA 2023 Annual Meeting & Exposition. Leppien explained further that chronic pain should be treated as its own disease state just like other conditions would be, such as diabetes, asthma, or...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Conferences / Podcast, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Trends
Walgreens to help bring cell and gene therapies to patients as it expands specialty pharmacy services
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
Walgreens To Launch $24 Billion Business Dedicated To Specialty Pharmacy
STAT+: Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future
Opinion: Shortages of generic drugs can’t be blamed solely on group purchasing organizations

Share This Article